Published Date: 29 Jul 2023
Whether a photo is taken in the first person or third person reflects the photographer's intention to either record the event's physical experience or its deeper meaning.
Read Full NewsAlmost immediately after Theresa Greco was diagnosed with breast cancer in March, doctors asked her whether she wanted to participate in a clinical trial. The trial would do high-powered radiation targeted at her tumor prior ...
Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting the protein essential to tumor cell growth and by adding a key signal to boost the immune system response. ...
Indoor hydroponic gardening—a method of growing plants using nutrient-rich water instead of soil—could help cancer patients develop better mental health, eat a healthier diet and enjoy a better overall quality of life.
In the United States, the incarcerated population is aging. About 15% of incarcerated adults, or approximately 175,000 people, are now 55 years or older.
1.
A Possible Novel CAR-T Treatment for High-Risk R/R Follicular Lymphoma May Be Liso-Cel.
2.
Higher Binge Drinking Rates Linked to New Cannabis Laws.
3.
Sports for girls are frequently abandoned due to uniform issues.
4.
MCh in Surgical Oncology: Admission, Medical School, Fees, Qualifications Information
5.
Benzene in Cold Med; Male Cancer Death to Rise 93%; Mail-Order Drugs Compromised?
1.
Gut microbiota in curing cancer
2.
Cardio-Oncology in Survivors: Safeguarding Hearts Through Multidisciplinary Care
3.
Understanding the Importance of CA125: A Comprehensive Guide
4.
Hemophilia: Pathophysiology, Genetics, and Treatment Advances
5.
Unlocking the Secrets of Blood Production: The Journey and Regulation of Hematopoietic Stem Cells
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
2.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation